Literature DB >> 26747254

3D-Flair sequence at 3T in cochlear otosclerosis.

Francesco Lombardo1, Sara De Cori2, Gayane Aghakhanyan2, Domenico Montanaro2, Daniele De Marchi2, Francesca Frijia2, Susanna Fortunato3, Francesca Forli3, Dante Chiappino4, Stefano Berrettini3, Raffaello Canapicchi2.   

Abstract

PURPOSE: To assess the capability of three-dimensional fluid-attenuated inversion recovery (3D-FLAIR) sequences in detecting signal alterations of the endolabyrinthine fluid in patients with otosclerosis.
MATERIALS AND METHODS: 3D-FLAIR before and after (-/+) gadolinium (Gd) administration was added to the standard MR protocol and acquired in 13 patients with a clinical/audiological diagnosis of severe/profound hearing loss in otosclerosis who were candidates for cochlear implantation and in 11 control subjects using 3-T magnetic resonance imaging (MRI) equipment. The MRI signal of the fluid-filled cochlea was assessed both visually and calculating the signal intensity ratio (SIR = signal intensity cochlea/brainstem).
RESULTS: We revealed no endocochlear signal abnormalities on T1-weighted -/+ Gd images for either group, while on 3D-FLAIR we found bilateral hyperintensity with enhancement after Gd administration in eight patients and bilateral hyperintensity without enhancement in one patient. No endocochlear signal abnormalities were detected in other patients or the control group.
CONCLUSION: Using 3-T MRI equipment, the 3D-FLAIR -/+ Gd sequence is able to detect the blood-labyrinth barrier (BLB) breakdown responsible for alterations of the endolabyrinthine fluid in patients with cochlear otosclerosis. We believe that 3D-FLAIR +/- Gd is an excellent imaging modality to assess the intra-cochlear damage in otosclerosis patients. KEY POINTS: • Gd-enhanced T1-weighted MRI has limited application to detect intra-cochlear damage. • 3D-FLAIR is less sensitive to flux artefacts and allows multiplanar reconstruction. • Post-Gd 3D-FLAIR is advantageous as it may highlight the BLB breakdown. • Using 3D-FLAIR -/+ Gd, we were able to identify intra-cochlear signal hyperintensities. • 3D-FLAIR might be applied for monitoring disease progression and treatment response.

Entities:  

Keywords:  3D imaging; 3D-FLAIR; MRI; Otosclerosis; Temporal bone

Mesh:

Substances:

Year:  2016        PMID: 26747254     DOI: 10.1007/s00330-015-4170-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  27 in total

Review 1.  Current research in otosclerosis.

Authors:  Konstantina M Stankovic; Michael J McKenna
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2006-10       Impact factor: 2.064

2.  CT grading of otosclerosis.

Authors:  T C Lee; R I Aviv; J M Chen; J M Nedzelski; A J Fox; S P Symons
Journal:  AJNR Am J Neuroradiol       Date:  2009-03-25       Impact factor: 3.825

3.  Visualization of endolymphatic hydrops in patients with Meniere's disease.

Authors:  Tsutomu Nakashima; Shinji Naganawa; Makoto Sugiura; Masaaki Teranishi; Michihiko Sone; Hideo Hayashi; Seiichi Nakata; Naomi Katayama; Ieda Maria Ishida
Journal:  Laryngoscope       Date:  2007-03       Impact factor: 3.325

4.  Signal intensity change of the labyrinth in patients with surgically confirmed or radiologically diagnosed vestibular schwannoma on isotropic 3D fluid-attenuated inversion recovery MR imaging at 3 T.

Authors:  In Ho Lee; Hyung-Jin Kim; Won Ho Chung; Eunhee Kim; Jung Won Moon; Sung Tae Kim; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

5.  Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.

Authors:  F Van Wijk; H Staecker; E Keithley; P P Lefebvre
Journal:  Audiol Neurootol       Date:  2006-09-21       Impact factor: 1.854

6.  Magnetic resonance imaging in the evaluation of clinical treatment of otospongiosis: a pilot study.

Authors:  Andy de Oliveira Vicente; Sujana S Chandrasekhar; Helio K Yamashita; Oswaldo Laercio M Cruz; Flavia A Barros; Norma O Penido
Journal:  Otolaryngol Head Neck Surg       Date:  2015-03-19       Impact factor: 3.497

7.  Markers of cochlear inflammation using MRI.

Authors:  Johann Le Floc'h; Winston Tan; Ravindra S Telang; Srdjan M Vlajkovic; Alfred Nuttall; William D Rooney; Beau Pontré; Peter R Thorne
Journal:  J Magn Reson Imaging       Date:  2013-04-15       Impact factor: 4.813

Review 8.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

9.  Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging findings in a patient with cochlear otosclerosis.

Authors:  Makoto Sugiura; Shinji Naganawa; Michihiko Sone; Tadao Yoshida; Tsutomu Nakashima
Journal:  Auris Nasus Larynx       Date:  2007-09-05       Impact factor: 1.863

10.  Otosclerosis and otospongiosis: clinical and histological comparisons.

Authors:  C Parahy; F H Linthicum
Journal:  Laryngoscope       Date:  1984-04       Impact factor: 3.325

View more
  3 in total

1.  3D fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging at different stages of otosclerosis.

Authors:  Stefano Berrettini; Francesco Lombardo; Luca Bruschini; Annalisa Ciabotti; Canapicchi Raffaello; Francesca Forli
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-06       Impact factor: 2.503

2.  Imaging Studies in Otosclerosis: An Up-to-date Comprehensive Review.

Authors:  Lucas Resende Lucinda Mangia; Luiz Otávio de Mattos Coelho; Bettina Carvalho; Adriana Kosma Pires de Oliveira; Rogerio Hamerschmidt
Journal:  Int Arch Otorhinolaryngol       Date:  2020-09-24

3.  MRI With Gadolinium as a Measure of Blood-Labyrinth Barrier Integrity in Patients With Inner Ear Symptoms: A Scoping Review.

Authors:  Christopher I Song; Jacob M Pogson; Nicholas S Andresen; Bryan K Ward
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.